Cobaltabis(dicarbollide) [o-COSAN]- loaded apoferritin: an innovative high-capacity boron delivery system to target tumour cells for BNCT applications
This study describes an innovative apoferritin-based nanohybrid, Apo:[o-COSAN]-, as a high-capacity boron delivery system for potential application in boron neutron capture therapy (BNCT). The nanohybrid is characterized by a high boron content, stability, and the promotion of biological interaction...
| Autores: | , , , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Recursos: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/394337 |
| Acesso em linha: | http://hdl.handle.net/10261/394337 https://api.elsevier.com/content/abstract/scopus_id/105003291535 |
| Access Level: | acceso abierto |
| Palavra-chave: | Neutron capture therapy Ferritin Nanoparticles |
| Resumo: | This study describes an innovative apoferritin-based nanohybrid, Apo:[o-COSAN]-, as a high-capacity boron delivery system for potential application in boron neutron capture therapy (BNCT). The nanohybrid is characterized by a high boron content, stability, and the promotion of biological interactions of cobaltabis(dicarbollide) ([o-COSAN]-), encapsulated within the apoferritin protein cavity through an acid-induced dissociation and reassembly process. The Apo:[o-COSAN]- nanohybrid demonstrated enhanced boron uptake in MCF7 breast cancer and AB22 mesothelioma cell lines, with superior stability and biocompatibility under physiological conditions. Notably, AB22 cells treated with Apo:[o-COSAN]- showed significant cytotoxic effects following neutron irradiation, highlighting the potential of this system in BNCT. These findings underscore the versatility of apoferritin as a multifunctional nanocarrier for targeted cancer therapy, combining high boron payloads with selective tumour cell uptake. |
|---|